Evidence map›Paper›PMID 33797652›Full record

Observational studyBreast cancer research and treatment2021

Cardioprotective medication use in Black and white breast cancer survivors.

Arnethea L Sutton, Ashley S Felix, Dipankar Bandyopadhyay, Reuben Retnam, William G Hundley, Vanessa B Sheppard

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Cardioprotection of High-Risk Individuals.Heart failure clinics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Arnethea L SuttonDepartment of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, P.O. Box 980149, Richmond, VA, 23219, USA. Arnethea.sutton@vcuhealth.org.ORCID http://orcid.org/0000-0002-4398-0278
Ashley S FelixDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.
Dipankar BandyopadhyayDepartment of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Reuben RetnamDepartment of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
William G HundleyDepartment of Internal Medicine, Division of Cardiovascular Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Vanessa B SheppardDepartment of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, P.O. Box 980149, Richmond, VA, 23219, USA.
Virginia Commonwealth University · USThe Ohio State University · USVirginia Department of Health · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Training Program in Cancer Prevention and Control and Cancer Health Equity (CPC-CHE)T32CA093423 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Bernard F Fuemmeler, Oxana G Palesh · 2018 to 2026
$3.0M
PREDICTORS OF ADJUVANT ENDOCRINE THERAPY ADHERENCE IN WOMEN WITH BREAST CANCERR01CA154848 · NCI · GEORGETOWN UNIVERSITY · PI SHEPPARD, VANESSA B · 2011 to 2015
$2.5M
Effect of adiposity changes on endometrial tissue and blood biomarkers in women at increased risk for endometrial cancerK01CA218457 · NCI · OHIO STATE UNIVERSITY · PI FELIX, ASHLEY S. · 2018 to 2022
$703k
Unpacking the Multi-level Drivers of Cardiotoxicity Disparities in Breast Cancer SurvivorsK99CA256038 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SUTTON, ARNETHEA LA'SHAUN · 2021 to 2022
$225k
NCATS NIH HHS UL1 TR002649NCATS NIH HHS UL1TR002649NCI NIH HHS 2T32CA093423NCI NIH HHS K01 CA218457NCI NIH HHS K01CA21845701A1NCI NIH HHS K99 CA256038NCI NIH HHS K99CA256038NCI NIH HHS P30 CA016059NCI NIH HHS P30CA016059NCI NIH HHS R01 CA154848NCI NIH HHS R01CA154848NCI NIH HHS T32 CA093423
6 · The paper itself

Abstract

purposeRacial disparities in cardiovascular disease and cardiac dysfunction exist amongst breast cancer survivors. This study examined the prevalence of cardioprotective medication use in survivors and identified factors associated with use by race.

methodsThe analysis included women enrolled in the Women's Hormonal Initiation and Persistence study, a longitudinal observational trial of breast cancer survivors. The study outcome, angiotensin converting enzyme inhibitor (ACEi) or ß-Blocker (BB) use, were ascertained from pharmacy records. Demographic, psychosocial, healthcare, and quality of life factors were collected from surveys and clinical data were abstracted from medical records. Bivariate associations by race and ACEi/BB use were tested using chi square and t tests; logistic regression evaluated multivariable-adjusted associations.

resultsOf the 246 survivors in the sample, 33.3% were Black and most were < 65 years of age (58.4%). Most survivors were hypertensive (57.6%) and one-third received ACEi/BBs. In unadjusted analysis, White women (vs. Black) (OR 0.33, 95% 0.19-0.58) and women with higher ratings of functional wellbeing (OR 0.94, 95% 0.89-0.99) were less likely to use ACEi/BBs. Satisfaction with provider communication was only significant for White women. In multivariable-adjusted analysis, ACEi/BB use did not differ by race. Correlates of ACEi/BB use included hypertension among all women and older age for Black women only.

conclusionsAfter adjusting for age and comorbidities, no differences by race in ACEi/BB use were observed. Hypertension was a major contributor of ACEi/BB use in BC survivors.

Indexed as

Breast NeoplasmsCancer SurvivorsAgedAngiotensin-Converting Enzyme InhibitorsBlack or African AmericanFemaleHumansQuality of LifeAngiotensin-Converting Enzyme InhibitorsAngiotensin converting enzyme inhibitorsBeta-blockersBreast cancerCardiovascular diseaseHypertension

Identifiers

PMID33797652
PMCPMC8277673
OpenAlexW3141856343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.